Advertisement
Letter to the Editor| Volume 86, ISSUE 3, P256-308, March 2023

Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,048 patients hospitalised during the 2016-17 and 2017-18  influenza seasons

Published:January 13, 2023DOI:https://doi.org/10.1016/j.jinf.2023.01.004
Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,048 patients hospitalised during the 2016-17 and 2017-18  influenza seasons
Previous ArticleFacial nerve palsy as a possible adverse drug reaction of the modified vaccinia ankara-bavarian nordic (MVA-BN) smallpox vaccine: A pharmacovigilance analysis
Next ArticleKlebsiella pneumoniae infection in the paediatric population before and after the COVID-19 pandemic in Shenzhen, China

      Abstract

      Standard course oseltamivir 75mg two times daily for five days was associated with an 82% reduction of odds of in-patient death (OR 0.18 (0.07,0.51)) compared to no oseltamivir treatment (OR 1.0 Reference) in a final multivariable logistic regression model of a retrospective cohort of PCR confirmed influenza B and influenza A (H3N2) infected patients admitted to a large UK teaching hospital in influenza seasons 2016-17 and 2017-18. No difference of protective odds for standard course oseltamivir was observed between influenza B and influenza A (H3N2) nor between influenza seasons. These observations strongly support clinical guidelines for molecular testing for respiratory viruses on admission to hospital and prompt treatment of confirmed seasonal influenza B and A with oseltamivir 75mg twice daily for five days.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Poole S
        • Brendish NJ
        • Clark TW
        SARS-CoV-2 has displaced other seasonal respiratory viruses: Results from a prospective cohort study.
        J Infect. 2020; 81: 966-972
        View in Article
        • United Kingdom Health Security Agency
        Weekly Influenza and COVID-19 Surveillance graphs. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1128595/Weekly_COVID-19_and_Influenza_Surveillance_Graphs__w2_report.pdf to.
        week. 2023; 1
        View in Article

      3. United Kingdom Health Security Agency. Guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058443/ukhsa-guidance-antivirals-influenza-11v4.pdf2021.

        View in Article
        • Hurt AC
        • Kelly H.
        Debate regarding oseltamivir use for seasonal and pandemic influenza.
        Emerg Infect Dis. 2016; 22: 949-955
        View in Article
        • Reacher M
        • Warne B
        • Reeve L
        • Verlander NQ
        • Jones NK
        • Ranellou K
        • et al.
        Influenza-associated mortality in hospital care: a retrospective cohort study of risk factors and impact of oseltamivir in an English teaching hospital, 2016 to 2017.
        Euro Surveill. 2019; 24
        View in Article

      Article info

      Publication history

      Published online: January 13, 2023
      Accepted: January 4, 2023

      Identification

      DOI: https://doi.org/10.1016/j.jinf.2023.01.004

      Copyright

      © 2023 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX